Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Acerta Pharma BV
Scientific Title
A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects With R/R Chronic Lymphocytic Leukemia